<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04388254</url>
  </required_header>
  <id_info>
    <org_study_id>PTI-125-04</org_study_id>
    <secondary_id>R44AG065152</secondary_id>
    <nct_id>NCT04388254</nct_id>
  </id_info>
  <brief_title>PTI-125, 100 mg, for Mild-to-moderate Alzheimer's Disease Patients</brief_title>
  <acronym>PTI-125</acronym>
  <official_title>A 12-Month, Open-Label Safety Study of PTI-125 in Mild-to-moderate Alzheimer's Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cassava Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Cassava Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-label study for patients who completed the previous studies, PTI-125-02 or
      PTI-125-03. Additional new patients will be included for a total of 100 patients enrolled for
      this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study are to establish 1-year safety and to investigate the effect of
      PTI-125 on biomarkers, cognition and neuropsychiatric symptoms during 12-month repeat-dose
      oral administration in mild-to-moderate AD patients, 50-85 years of age.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Approximately one hundred (100) patients will be enrolled into the study. The patients will receive PTI-125, 100 mg b.i.d.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebrospinal fluid P-tau, neurofilament light chain, neurogranin, Total Tau, YKL-40, Abeta42 (pg/mL)</measure>
    <time_frame>Screening to Month 12</time_frame>
    <description>Biomarkers of AD pathology, neurodegeneration and neuroinflammation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>PTi-125, 100 mg tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTI-125, 100 mg oral tablets administered twice daily (BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTI-125, 100 mg tablet</intervention_name>
    <description>PTI-125 100 mg oral tablet</description>
    <arm_group_label>PTi-125, 100 mg tablets</arm_group_label>
    <other_name>PTI-125</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent form (ICF) signed by the subject or legally acceptable
             representative.

          -  Patient has a caregiver or legal respresentative responsible for administering the
             drug and recording the time.

          -  Ages &gt;= 50 and &lt;= 85 years (upper limit waived for prior PTI-125 study participants)

          -  Clinical diagnosis of dementia due to possible or probable Alzheimer's disease

          -  If female, postmenopausal for at least 1 year

          -  Patient living at home, senior residential setting, or an institutional setting
             without the need for continuous (i.e. 24-h) nursing care

          -  General health status acceptable for participation in the study

          -  Fluency (oral and written) in English or Spanish

          -  If receiving memantine, rivastigmine, galantamine or an AChEI, receiving a stable dose
             for at least 3 months. If receiving donepezil, any dose lower than 23 mg once daily.
             Multiple medications are allowed.

          -  The patient is a non-smoker for at least 3 years.

          -  The patient or legal representative must agree to comply with the drawing of blood
             samples, laboratory assessments and for new patients or patients starting &lt; 30 days
             form the last PTI-125 study, with a lumbar puncture and the drawing of cerebrospinal
             fluid samples for biomarker assessments.

        Additional Criteria for NEW patients:

          -  The patient has a ratio of total tau/AÎ²42 in cerebrospinal fluid &gt;= 0.28.

          -  MMSE score &gt;= 16 and &lt;=26 at screening, OR if &gt; 26, must have evidence of AD pathology
             such as a prior CSF total tau/AB42 ratio &gt;=0.28, an amyloid positive PET scan or
             hippocampal volume loss consistent with AD.

        Exclusion Criteria:

          -  Anything in the opinion of the Investigator would preclude participation in a 1-year
             study.

          -  Positive urine drug test at screening

          -  Positive HIV, HCV or HbsAg screen

          -  Suicidality on C-SSRS

          -  Exposure to an experimental drug other than PTI-125, experimental biologic or
             experimental medical device within the longer of 5 half-lives or 3 months before
             screening

          -  A medical condition that would interfere with a lumbar puncture

          -  Residence in a skilled nursing facility and requiring 24 h care.

          -  Clinically significant laboratory test results

          -  Clinically significant untreated hypothyroidism

          -  Insufficiently controlled diabetes mellitus

          -  Renal insufficiency (serum creatinine &gt; ULN and clinically signigicant in the opinion
             of PI and/or Sponsor)

          -  Malignant tumor within 3 years before screening (except squamous and basal cell
             carcinoma or cervical carcinoma in situ or localized prostate cancer or localized
             stage 1 bladder cancer)

          -  History of ischemic colitis or ischemic enterocolitis

          -  Unstable medical condition that is clinically significant in the judgment of the
             investigator

          -  Alanine transaminase (ALT) or aspartate transaminase (AST) &gt; ULN or total bilirubin &gt;
             ULN and clinically significant in the opinion of PI and/or Sponsor.

          -  History of myocardial infarction or unstable angina within 6 months before screening

          -  History of more than 1 myocardial infarction within 5 years before screening

          -  Clinically significant cardiac arrhythmia (including atrial fibrillation),
             cardiomyopathy, or cardiac conduction defect (patients with a pacemaker are
             acceptable)

          -  Symptomatic hypotension, or uncontrolled hypertension

          -  Clinically significant abnormality on screening electrocardiogram (ECG), including but
             not necessarily limited to a confirmed corrected QT interval value &gt;= 450 msec for
             males or &gt;= 470 msec for females.

          -  Stroke within 18 months before screening, or history of a stroke concomitant with
             onset of dementia

          -  History of brain tumor or other clinically significant space-occupying lesion on CT or
             MRI

          -  Head trauma with clinically significant loss of consciousness within 12 months before
             screening or concurrent with the onset of dementia

          -  Onset of dementia secondary to cardiac arrest, surgery with general anesthesia, or
             resuscitation

          -  Specific degenerative Central Nervous System disease diagnosis other than Alzheimer's
             disease (eg, Huntington's disease, Creutzfeld-Jacob disease, Down's syndrome,
             Frontotemporal Dementia, Parkinson's disease)

          -  Wernicke's encephalopathy

          -  Active acute or chronic Central Nervous System infection

          -  Donepezil 23 mg or greater QD currently or within 3 months prior to randomization

          -  Discontinued AChEI &lt; 30 days prior to randomization

          -  Antipsychotics; low doses are allowed only if given for sleep disturbances, agitation
             and/or aggression, and only if the subject has received a stable dose for at least 3
             months before randomization

          -  Tricyclic antidepressants and monoamine oxidase inhibitors; all other antidepressants
             are allowed only if the subject has received a stable dose for at least 3 months
             before randomization.

          -  Anxiolytics or sedative-hypnotics, including barbiturates (unless given in low doses
             for benign tremor); low doses of benzodiazepines and zolpidem are allowed only if
             given for insomnia/sleep disturbance, and only if the subject has received a stable
             dose for at least 3 months before randomization.

          -  Immunosuppressants, including systemic corticosteroids, if taken in clinically
             immunosuppressive doses (Steroid use for allergy or other inflammation is permitted.)

          -  Antiepileptic medications if taken for control of seizures

          -  Chronic intake of opioid-containing analgesics

          -  Sedating H1 antihistamines

          -  Nicotine therapy (all dosage forms including a patch), varenicline (Chantix), or
             similar therapeutic agent within 30 days before screening

          -  Clinically significant illness within 30 days of enrollment

          -  History of significant neurological, hepatic, renal, endocrine, cardiovascular,
             gastrointestinal, pulmonary, or metabolic disease

          -  Loss of a significant volume of blood (&gt; 450 mL) within 4 weeks prior to the study

          -  COVID-19 infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsay Burns, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Cassava Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lindsay Burns, PhD</last_name>
    <phone>512-501-2484</phone>
    <email>lburns@cassavasciences.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carrie Crowley, BA</last_name>
    <phone>512-501-2453</phone>
    <email>ccrowley@cassavasciences.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cognitive Clinical Trials</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85296</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niki Rathbun</last_name>
      <phone>480-653-8212</phone>
      <email>nikirathbun@cctresearch.com</email>
    </contact>
    <investigator>
      <last_name>Brian Beck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cognitive Clinical Trials</name>
      <address>
        <city>Surprise</city>
        <state>Arizona</state>
        <zip>85374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Thomas</last_name>
      <phone>480-530-2093</phone>
      <email>georgethomas@cctresearch.com</email>
    </contact>
    <investigator>
      <last_name>Patrick Sciara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Optimus U</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lainet Infante</last_name>
      <phone>305-702-0024</phone>
      <email>infante@optimusu.com</email>
    </contact>
    <contact_backup>
      <last_name>Klemnys Romero</last_name>
      <phone>305-702-0024</phone>
      <email>romero@optimusu.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yaneicy Gonzalez-Rojas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IMIC, Inc.</name>
      <address>
        <city>Palmetto Bay</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minela Sulijicic-Martinez</last_name>
      <phone>786-310-7477</phone>
      <email>minela@aktamedika.com</email>
    </contact>
    <investigator>
      <last_name>Evelyn Lopez-Brignoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cognitive Clinical Trials</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Diederich</last_name>
      <phone>402-509-2920</phone>
      <email>heatherdiederich@cctresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Colleen Caliri</last_name>
      <phone>402-315-9218</phone>
      <email>colleencaliri@cctresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>John Puente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cognitive Clinical Trials</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Caliri</last_name>
      <phone>402-315-9218</phone>
      <email>colleencaliri@cctresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Heather Diederich</last_name>
      <phone>402-509-2920</phone>
      <email>heatherdiederich@cctresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tamara A Doehner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Memory Research Institute</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Carey</last_name>
      <phone>732-341-9500</phone>
      <email>jcarey@amrinj.com</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Bawriec</last_name>
      <phone>732-341-9500</phone>
    </contact_backup>
    <investigator>
      <last_name>Sanjiv Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shruti Konda</last_name>
      <phone>281-282-0808</phone>
      <email>skonda@centexstudies.com</email>
    </contact>
    <contact_backup>
      <last_name>Tara Green</last_name>
      <phone>281-282-0808</phone>
      <email>tgreen@centexstudies.com</email>
    </contact_backup>
    <investigator>
      <last_name>Joe E Pouzar, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centex Studies</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Gurrola</last_name>
      <phone>346-801-3326</phone>
      <email>joannagurrola@centexstudies.com</email>
    </contact>
    <investigator>
      <last_name>Joel Solis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

